Provided by Tiger Trade Technology Pte. Ltd.

Stoke Therapeutics, Inc.

24.74
+0.79003.30%
Post-market: 25.000.2600+1.05%16:42 EDT
Volume:704.95K
Turnover:17.46M
Market Cap:1.60B
PE:-7.42
High:25.20
Open:23.98
Low:23.79
Close:23.95
52wk High:40.22
52wk Low:20.32
Shares:64.53M
Float Shares:45.61M
Volume Ratio:0.82
T/O Rate:1.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3325
EPS(LYR):-0.1163
ROE:-61.10%
ROA:-35.87%
PB:4.62
PE(LYR):-212.79

Loading ...

Stoke Therapeutics Completes Dosing in First Two Cohorts of Phase 1 Osprey Trial for STK-002 in Optic Atrophy

Reuters
·
Oct 06

Stoke Therapeutics Announces Presentations of Stk-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (Adoa), at the American Academy of Ophthalmology (Aao) 2026 Annual Meeting

THOMSON REUTERS
·
Oct 06

Stoke Therapeutics Targets Early 2028 U.S. Launch for Dravet Drug Zorevunersen After FDA Alignment Meeting

Reuters
·
Oct 05

Stoke - Phase 3 Emperor Study Readout Anticipated Q3 2027; Nda Submission Planned H2 2027

THOMSON REUTERS
·
Oct 05

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. Nda for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

THOMSON REUTERS
·
Oct 05

Stoke Therapeutics Chief Medical Officer Barry Ticho Disposes of Shares Worth $27,491.51

Reuters
·
Oct 03

Stoke Therapeutics Director Alexander Cumbo Files Initial Beneficial Ownership Statement

Reuters
·
Sep 26

Stoke Therapeutics Appoints Alexander “Bo” Cumbo to Board After Edward Kaye Resigns

Reuters
·
Sep 26

Stoke Therapeutics names Bo Cumbo to board of directors

TIPRANKS
·
Sep 24

Stoke Therapeutics Names Solid Biosciences CEO Bo Cumbo to Board

Reuters
·
Sep 24

Stoke Therapeutics Appoints Bo Cumbo to Its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

THOMSON REUTERS
·
Sep 24

Stoke Therapeutics Grants Inducement Stock Options for 53,175 Shares at USD 28.15 Each

Reuters
·
Sep 17

Stoke Therapeutics, Biogen present long-term data on Zorevunersen

TIPRANKS
·
Sep 04

Stoke Therapeutics, Biogen Report 4-Year Open-Label Data for Dravet Drug Zorevunersen Showing Durable Seizure Reduction

Reuters
·
Sep 04

Stoke Therapeutics and Biogen Present Long-Term Clinical Data That Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16TH European Epilepsy Congress (Eec)

THOMSON REUTERS
·
Sep 04

Stoke Therapeutics CMO Barry Ticho Sells 5,545 Shares for $169,164.19

Reuters
·
Sep 04

Stoke Therapeutics CEO, Chief Patient Officer to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 02

Stoke Therapeutics Says Phase 3 Emperor Trial of Dravet Drug Zorevunersen is Underway, Results Due Q3 2027

Reuters
·
Sep 01

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16TH European Epilepsy Congress (Eec)

THOMSON REUTERS
·
Sep 01

U.S. Stocks on the MOVE-Ubiquiti, BJ's Wholesale, Arbutus

Reuters
·
Aug 21